Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

JetBlue Airways Corp JBLU

JetBlue Airways Corporation is a travel company. It provides air transportation services across the United States, the Caribbean, Latin America, Canada and the United Kingdom. Its segments include Domestic, and Caribbean & Latin America. It operates five types of aircraft: Airbus A220, Airbus A320, Airbus A321, Airbus A321neo, and Embraer E190. Airbus A220 aircraft have 140 seats in a single cabin layout. It has eight of Airbus A220 aircraft in its fleet. Airbus A320 aircraft in the classic configuration have 150 seats and those A320 aircraft, which have gone through its cabin restyling program have 162 seats. It has 113 restyled Airbus A320 aircraft in service. Airbus A321 aircraft in a single cabin layout have 200 seats and those with its Mint offering have 159 seats. Airbus A321neo aircraft have 200 seats and those with its Mint offering have 160 seats. The long-range version of its A321neo aircraft with Mint offering have 138 seats while its Embraer E190 aircraft have 100 seats.


NDAQ:JBLU - Post by User

User Avatar Image
(0)
•••
  • KarenCarX
Post by KarenCaron Apr 15, 2022 8:47am
61 Views
Post# 34606182

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS Video


FSD Pharma is delighted to announce pre-clinical findings indicating the efficacy of Lucid-MS, its flagship medication candidate, in treating Multiple Sclerosis. Lucid-MS's therapeutic potential is an industry first, and we'd like to provide visual evidence of functional recovery in pre-clinical individuals in this video!

<< Previous
Bullboard Posts
Next >>